Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST)

International Journal of Drug Policy

Volumn 18, Issue 4, 2007, Pages 262-270

  Spire, Bruno ^a   Lucas, Gregory M ^b   Carrieri, M Patrizia ^a  

^a INSERM   (France)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adherence; Anti retroviral treatment; HIV; Injecting drug users; Substitution treatment

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; CANNABIS;

COMORBIDITY; CORRELATION ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG UTILIZATION; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTING DRUG USER; LONG TERM CARE; METHADONE TREATMENT; OPIOID SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOLOGICAL ASPECT; SHORT SURVEY; SOCIAL ASPECT; SOCIAL STATUS; SOCIAL SUPPORT; SUBSTITUTION THERAPY; THERAPY DELAY; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BUPRENORPHINE; HIV INFECTIONS; HUMANS; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34547204561     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2006.12.014     Document Type: Short Survey

References (99)

1. Aceijas C., Stimson G.V., Hickman M., and Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18 17 (2004) 2295-2303
2. Altice F.L., Friedland G.H., and Cooney E.L. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13 8 (1999) 957-962
3. Ammassari A., Antinori A., Aloisi M.S., Trotta M.P., Murri R., Bartoli L., et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active anti-retroviral therapy among HIV-infected persons. Psychosomatics 45 5 (2004) 394-402
4. Ammassari A., Murri R., Pezzotti P., Trotta M.P., Ravasio L., De Longis P., et al. Self-reported symptoms and medication side effects influence adherence to highly active anti-retroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. 28 5 (2001) 445-449
5. Andreo C., Bouhnik A.D., Soletti J., Bertholon D.R., Moatti J.P., Rossert H., et al. Non-compliance in HIV-infected patients, supported by a community association. Sante Publique 13 3 (2001) 249-262
6. Angelino A.F., and Treisman G.J. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 33 6 (2001) 847-856
7. Anon. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 280 22 (1998) 1936-1943
8. Arnsten J.H., Demas P.A., Grant R.W., Gourevitch M.N., Farzadegan H., Howard A.A., et al. Impact of active drug use on anti-retroviral therapy adherence and viral suppression in HIV-infected drug users. J. Gen. Intern. Med. 17 5 (2002) 377-381
9. Bangsberg D.R., Acosta E.P., Gupta R., Guzman D., Riley E.D., Harrigan P.R., et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20 2 (2006) 223-231
10. Bangsberg D.R., Charlebois E.D., Grant R.M., Holodniy M., Deeks S.G., Perry S., et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17 13 (2003) 1925-1932
11. Bangsberg D.R., Perry S., Charlebois E.D., Clark R.A., Roberston M., Zolopa A.R., et al. Non-adherence to highly active anti-retroviral therapy predicts progression to AIDS. AIDS 15 9 (2001) 1181-1183
12. Bassetti S., Battegay M., Furrer H., Rickenbach M., Flepp M., Kaiser L., et al. Why is highly active anti-retroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J. Acquir. Immune Defic. Syndr. 21 2 (1999) 114-119
13. Berg K.M., Demas P.A., Howard A.A., Schoenbaum E.E., Gourevitch M.N., and Arnsten J.H. Gender differences in factors associated with adherence to anti-retroviral therapy. J. Gen. Intern. Med. 19 11 (2004) 1111-1117
14. Bouhnik A.D., Carrieri M.P., Rey D., Spire B., Gastaut J.A., Gallais H., et al. Drug injection cessation among HIV-infected injecting drug users. Addict. Behav. 29 6 (2004) 1189-1197
15. Bouhnik A.D., Chesney M., Carrieri P., Gallais H., Moreau J., Moatti J.P., et al. Nonadherence among HIV-infected injecting drug users: The impact of social instability. J. Acquir. Immune Defic. Syndr. 31 Suppl. 3 (2002) S149-S153
16. Bouhnik A.D., Preau M., Vincent E., Carrieri M.P., Gallais H., Lepeu G., et al. Depression and clinical progression in HIV-infected drug users treated with highly active anti-retroviral therapy. Antivir. Ther. 10 1 (2005) 53-61
17. Brook M.G., Dale A., Tomlinson D., Waterworth C., Daniels D., and Forster G. Adherence to highly active anti-retroviral therapy in the real world: Experience of twelve English HIV units. AIDS Patient Care STDS 15 9 (2001) 491-494
18. Brooner R.K., King V.L., Kidorf M., Schmidt Jr. C.W., and Bigelow G.E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch. Gen. Psychiatry 54 1 (1997) 71-80
19. Carpenter C.C., Fischl M.A., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., et al. Anti-retroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. JAMA 280 1 (1998) 78-86
20. Carrieri M.P., Chesney M.A., Spire B., Loundou A., Sobel A., Lepeu G., et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int. J. Behav. Med. 10 1 (2003) 1-14
21. Carrieri M.P., Leport C., Protopopescu C., Cassuto J.P., Bouvet E., Peyramond D., et al. Factors associated with nonadherence to highly active anti-retroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J. Acquir. Immune Defic. Syndr. 41 4 (2006) 477-485
22. Carrieri M.P., Moatti J.P., Vlahov D., Obadia Y., Reynaud-Maurupt C., and Chesney M. Access to anti-retroviral treatment among French HIV infected injection drug users: The influence of continued drug use. MANIF 2000 Study Group. J. Epidemiol. Community Health 53 1 (1999) 4-8
23. Carrieri M.P., Raffi F., Lewden C., Sobel A., Michelet C., Cailleton V., et al. Impact of early versus late adherence to highly active anti-retroviral therapy on immuno-virological response: A 3-year follow-up study. Antivir. Ther. 8 6 (2003) 585-594
24. Carrieri M.P., Rey D., Loundou A., Lepeu G., Sobel A., and Obadia Y. Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug Alcohol Depend. 72 1 (2003) 13-21
25. Carrieri P., Cailleton V., Le Moing V., Spire B., Dellamonica P., Bouvet E., et al. The dynamic of adherence to highly active anti-retroviral therapy: Results from the French National APROCO Cohort. J. Acquir. Immune Defic. Syndr. 28 3 (2001) 232-239
26. Carrieri P., Spire B., Duran S., Katlama C., Peyramond D., Francois C., et al. Health-related quality of life after 1 year of highly active anti-retroviral therapy. J. Acquir. Immune Defic. Syndr. 32 1 (2003) 38-47
27. Celerier E., Laulin J.P., Corcuff J.B., Le Moal M., and Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization process. J. Neurosci. 21 11 (2001) 4074-4080
28. Chaisson R.E., Keruly J.C., and Moore R.D. Race, sex, drug use, and progression of human immunodeficiency virus disease. N. Engl. J. Med. 333 12 (1995) 751-756
29. Chesney M.A. Factors affecting adherence to anti-retroviral therapy. Clin. Infect. Dis. 30 S2 (2000) S171-S176
30. Chesney M.A., Morin M., and Sherr L. Adherence to HIV combination therapy. Soc. Sci. Med. 50 11 (2000) 1599-1605
31. Clarke S., Keenan E., Ryan M., Barry M., and Mulcahy F. Directly observed anti-retroviral therapy for injection drug users with HIV infection. AIDS Read. 12 7 (2002) pp. 305-307, 312-306
32. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23 8 (2001) 1296-1310
33. Compton P., Charuvastra V.C., and Ling W. Pain intolerance in opiate-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug Alcohol Depend. 63 2 (2001) 139-146
34. Conway B., Prasad J., Reynolds R., Farley J., Jones M., Jutha S., et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin. Infect. Dis. 38 Suppl. 5 (2004) S402-S408
35. Cruess D.G., Douglas S.D., Petitto J.M., Leserman J., Ten Have T., Gettes D., et al. Association of depression, CD8+ T lymphocytes, and natural killer cell activity: Implications for morbidity and mortality in human immunodeficiency virus disease. Curr. Psychiatry Rep. 5 6 (2003) 445-450
36. Duburcq A., Charpak Y., Blin P., and Madec L. Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex). Rev. Epidemiol. Sante Publique 48 4 (2000) 363-373
37. Duran S., Saves M., Spire B., Cailleton V., Sobel A., Carrieri P., et al. Failure to maintain long-term adherence to highly active anti-retroviral therapy: The role of lipodystrophy. AIDS 15 18 (2001) 2441-2444
38. Duran S., Spire B., Raffi F., Walter V., Bouhour D., Journot V., et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin. Trials 2 1 (2001) 38-45
39. Gerbert B., Maguire B.T., Bleecker T., Coates T.J., and McPhee S.J. Primary care physicians and AIDS. Attitudinal and structural barriers to care. JAMA 266 20 (1991) 2837-2842
40. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug Alcohol Depend. 75 1 (2004) 37-45
41. Gibson D.R., Sorensen J.L., Wermuth L., and Bernal G. Families are helped by drug treatment. Int. J. Addict. 27 8 (1992) 961-978
42. Gifford A.L., Bormann J.E., Shively M.J., Wright B.C., Richman D.D., and Bozzette S.A. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug anti-retroviral regimens. J. Acquir. Immune Defic. Syndr. 23 5 (2000) 386-395
43. Golub E.T., Astemborski J.A., Hoover D.R., Anthony J.C., Vlahov D., and Strathdee S.A. Psychological distress and progression to AIDS in a cohort of injection drug users. J. Acquir. Immune Defic. Syndr. 32 4 (2003) 429-434
44. Gonzalez J.S., Penedo F.J., Antoni M.H., Duran R.E., McPherson-Baker S., Ironson G., et al. Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol. 23 4 (2004) 413-418
45. Gourevitch M.N., and Friedland G.H. Interactions between methadone and medications used to treat HIV infection: A review. Mt. Sinai J. Med. 67 5/6 (2000) 429-436
46. HIV Prevention Trials Network HPTN 058: A phase III randomized controlled trial to evaluate the efficacy of buprenorphine/naloxone drug treatment in prevention of HIV infection among opiate dependent injectors. Retrieved September 2005.
47. Hogg R., Yip B., Chan K., O'Shaughnessy M., and Montaner J. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. Paper presented at the XIIIth International AIDS conference. Durban (2000, July 9-14)
48. Hubbard R.L., Craddock S.G., and Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J. Subst. Abuse Treat. 25 3 (2003) 125-134
49. Ickovics J.R., Hamburger M.E., Vlahov D., Schoenbaum E.E., Schuman P., Boland R.J., et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study. JAMA 285 11 (2001) 1466-1474
50. Ickovics J.R., and Meade C.S. Adherence to anti-retroviral therapy among patients with HIV: A critical link between behavioral and biomedical sciences. J. Acquir. Immune Defic. Syndr. 31 Suppl. 3 (2002) S98-S102
51. Kakko J., Svanborg K.D., Kreek M.J., and Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 361 9358 (2003) 662-668
52. Kalichman S.C., Ramachandran B., and Catz S. Adherence to combination anti-retroviral therapies in HIV patients of low health literacy. J. Gen. Intern. Med. 14 5 (1999) 267-273
53. Kapadia F., Vlahov D., Donahoe R.M., and Friedland G. The role of substance abuse in HIV disease progression: Reconciling differences from laboratory and epidemiologic investigations. Clin. Infect. Dis. 41 7 (2005) 1027-1034
54. Katzenstein D.A. Adherence as a particular issue with protease inhibitors. J. Assoc. Nurses AIDS Care 8 Suppl. (1997) 10-17
55. Kerr T., Palepu A., Barness G., Walsh J., Hogg R., Montaner J., et al. Psychosocial determinants of adherence to highly active anti-retroviral therapy among injection drug users in Vancouver. Antivir. Ther. 9 3 (2004) 407-414
56. Kleeberger C.A., Buechner J., Palella F., Detels R., Riddler S., Godfrey R., et al. Changes in adherence to highly active anti-retroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS 18 4 (2004) 683-688
57. Kleeberger C.A., Phair J.P., Strathdee S.A., Detels R., Kingsley L., and Jacobson L.P. Determinants of heterogeneous adherence to HIV-anti-retroviral therapies in the Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 26 1 (2001) 82-92
58. Kott A., Habel E., and Nottingham W. Analysis of behavioral patterns in five cohorts of patients retained in methadone maintenance programs. Mt. Sinai J. Med. 68 1 (2001) 46-54
59. Lloyd-Smith E., Brodkin E., Wood E., Kerr T., Tyndall M.W., Montaner J.S., et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 20 3 (2006) 445-450
60. Lucas G.M., Gebo K.A., Chaisson R.E., and Moore R.D. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16 5 (2002) 767-774
61. Lucas G.M., Griswold M., Gebo K.A., Keruly J., Chaisson R.E., and Moore R.D. Illicit drug use and HIV-1 disease progression: A longitudinal study in the era of highly active anti-retroviral therapy. Am. J. Epidemiol. 163 5 (2006) 412-420
62. Lucas G.M., Weidle P.J., Hader S., and Moore R.D. Directly administered anti-retroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clin. Infect. Dis. 38 Suppl. 5 (2004) S409-S413
63. Lyles C.M., Margolick J.B., Astemborski J., Graham N.M., Anthony J.C., Hoover D.R., et al. The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users. AIDS 11 10 (1997) 1255-1262
64. Maisels L., Steinberg J., and Tobias C. An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDS 15 4 (2001) 185-191
65. Marimoutou C., Carrieri P., Poizot-Martin I., Loundou A., Tremolieres F., Rey D., et al. Hospitalization for depressive syndrome in a cohort of HIV-infected patients contaminated through injecting drug use: MANIF 2000 cohort, France, 1995-1999. AIDS Care 15 5 (2003) 729-734
66. Marzolini C., Troillet N., Telenti A., Baumann P., Decosterd L.A., and Eap C.B. Efavirenz decreases methadone blood concentrations. AIDS 14 9 (2000) 1291-1292
67. McCance-Katz E.F., Rainey P.M., Smith P., Morse G., Friedland G., Gourevitch M., et al. Drug interactions between opioids and anti-retroviral medications: Interaction between methadone, LAAM, and nelfinavir. Am. J. Addict. 13 2 (2004) 163-180
68. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., and O'Brien C.P. The effects of psychosocial services in substance abuse treatment. JAMA 269 15 (1993) 1953-1959
69. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. J. Acquir. Immune Defic. Syndr. 6 9 (1993) 1049-1056
70. Moatti J.P., Carrieri M.P., Spire B., Gastaut J.A., Cassuto J.P., and Moreau J. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 14 2 (2000) 151-155
71. Moore R.D., Keruly J.C., and Chaisson R.E. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J. Acquir. Immune Defic. Syndr. 35 1 (2004) 46-51
72. Palepu A., Horton N.J., Tibbetts N., Meli S., and Samet J.H. Uptake and adherence to highly active anti-retroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction 99 3 (2004) 361-368
73. Palepu A., Tyndall M.W., Joy R., Kerr T., Wood E., Press N., et al. Anti-retroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug Alcohol Depend. 84 2 (2006) 188-194
74. Pinheiro C.A., de-Carvalho-Leite J.C., Drachler M.L., and Silveira V.L. Factors associated with adherence to anti-retroviral therapy in HIV/AIDS patients: A cross-sectional study in Southern Brazil. Braz. J. Med. Biol. Res. 35 10 (2002) 1173-1181
75. Pradier C., Bentz L., Spire B., Tourette-Turgis C., Morin M., Souville M., et al. Efficacy of an educational and counseling intervention on adherence to highly active anti-retroviral therapy: French prospective controlled study. HIV Clin. Trials 4 2 (2003) 121-131
76. Reno R.R., and Aiken L.S. Life activities and life quality of heroin addicts in and out of methadone treatment. Int. J. Addict. 28 3 (1993) 211-232
77. Richter A., and Loomis B. Health and economic impacts of an HIV intervention in out of treatment substance abusers: Evidence from a dynamic model. Health Care Manage. Sci. 8 1 (2005) 67-79
78. Rompalo A.M., Shah N., Margolick J.B., Farzadegan H., Arnsten J., Schuman P., et al. Evaluation of possible effects of continued drug use on HIV progression among women. Int. J. STD AIDS 15 5 (2004) 322-327
79. Russell J., Krantz S., and Neville S. The patient-provider relationship and adherence to highly active anti-retroviral therapy. J. Assoc. Nurses AIDS Care 15 5 (2004) 40-47
80. Sambamoorthi U., Warner L.A., Crystal S., and Walkup J. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug Alcohol Depend. 60 1 (2000) 77-89
81. Sethi A.K., Celentano D.D., Gange S.J., Moore R.D., and Gallant J.E. Association between adherence to anti-retroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37 8 (2003) 1112-1118
82. Shakarishvili A., Dubovskaya L.K., Zohrabyan L.S., St Lawrence J.S., Aral S.O., Dugasheva L.G., et al. Sex work, drug use, HIV infection, and spread of sexually transmitted infections in Moscow, Russian Federation. Lancet 366 9479 (2005) 57-60
83. Simoni J.M., Frick P.A., Pantalone D.W., and Turner B.J. Anti-retroviral adherence interventions: A review of current literature and ongoing studies. Top. HIV Med. 11 6 (2003) 185-198
84. Singh N., Squier C., Sivek C., Wagener M., Nguyen M., and Yu V. Determinants of compliance with anti-retroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 8 3 (1996) 261-269
85. Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., & Moatti, J. (in press). Adherence to highly active anti-retroviral therapy (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Soc. Sci. Med.
86. Spire B., Duran S., Souville M., Leport C., Raffi F., and Moatti J.P. Adherence to highly active anti-retroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Soc. Sci. Med. 54 10 (2002) 1481-1496
87. Stein M.D., Rich J.D., Maksad J., Chen M.H., Hu P., Sobota M., et al. Adherence to anti-retroviral therapy among HIV-infected methadone patients: Effect of ongoing illicit drug use. Am. J. Drug Alcohol Abuse 26 2 (2000) 195-205
88. Stone V., Clarke J., Lovell J., Steger K., Hirschhorn L., Boswell S., et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J. Gen. Intern. Med. 13 9 (1998) 586-593
89. Stone V.E. Strategies for optimizing adherence to highly active anti-retroviral therapy: Lessons from research and clinical practice. Clin. Infect. Dis. 33 6 (2001) 865-872
90. Tucker J.S., Burnam M.A., Sherbourne C.D., Kung F.Y., and Gifford A.L. Substance use and mental health correlates of nonadherence to anti-retroviral medications in a sample of patients with human immunodeficiency virus infection. Am. J. Med. 114 7 (2003) 573-580
91. Turner B.J., Laine C., Cosler L., and Hauck W.W. Relationship of gender, depression, and health care delivery with anti-retroviral adherence in HIV-infected drug users. J. Gen. Intern. Med. 18 4 (2003) 248-257
92. Wagner G.J., and Ryan G.W. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care STDS 18 7 (2004) 385-393
93. Walsh J.C., Pozniak A.L., Nelson M.R., Mandalia S., and Gazzard B.G. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of anti-retroviral drug resistance. J. Acquir. Immune Defic. Syndr. 30 3 (2002) 278-287
94. Wood E., Hogg R.S., Kerr T., Palepu A., Zhang R., and Montaner J.S. Impact of accessing methadone on the time to initiating HIV treatment among anti-retroviral-naive HIV-infected injection drug users. AIDS 19 8 (2005) 837-839
95. Wood E., Hogg R.S., Yip B., Harrigan P.R., O'Shaughnessy M.V., and Montaner J.S. The impact of adherence on CD4 cell count responses among HIV-infected patients. J. Acquir. Immune Defic. Syndr. 35 3 (2004) 261-268
96. Wood E., Montaner J.S., Yip B., Tyndall M.W., Schechter M.T., O'Shaughnessy M.V., et al. Adherence and plasma HIV RNA responses to highly active anti-retroviral therapy among HIV-1 infected injection drug users. Cmaj 169 7 (2003) 656-661
97. Woolridge E., Barton S., Samuel J., Osorio J., Dougherty A., and Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J. Pain Symptom Manage. 29 4 (2005) 358-367
98. Wu A.W., Ammassari A., and Antinori A. Adherence to anti-retroviral therapy: Where are we, and where do we go from here?. J. Acquir. Immune Defic. Syndr. 31 Suppl. 3 (2002) S95-S97
99. Yun L.W., Maravi M., Kobayashi J.S., Barton P.L., and Davidson A.J. Antidepressant treatment improves adherence to anti-retroviral therapy among depressed HIV-infected patients. J. Acquir. Immune Defic. Syndr. 38 4 (2005) 432-438